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Summary We have studied the relationship between expression of genes implicated in mediating resistance to cleavable complex-forming
topoisomerase 11 (topo 11) inhibitors and cellular sensitivity to ICRF-159, a 'catalytic' inhibitor of topo 11. Overexpression of the membrane
transporters, P-glycoprotein and multidrug resistance-related protein (MRP), ordown-regulation of topo lla and/or-1, did not confer ICRF-159
resistance. Indeed, marked topo Ila down-regulation appeared to be associated with collateral sensitivity to ICRF-159. Our results indicate
that the resistance mechanisms that pertain to cleavable complex-forming topo 11 inhibitors and ICRF-159 are distinct. The evidence
presented here suggests that topo lla, not topo llp, is more likely to be the major in vivo target for ICRF-159.
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Topo II has been identified as the primary cellular target for many
of the most effective and widely used anti-cancer drugs, including
etoposide, mitoxantrone, epirubicin and doxorubicin (reviewed in
Pommier, 1993; Froelich-Ammon and Osheroff, 1995). However,
the development of drug resistance limits the clinical efficacy of
these topo II-targeting agents. The best characterized mechanism of
resistance to topo II-targeting drugs is a change in drug accumula-
tion mediated by alterations in the expression of the multidrug
resistance protein, P-glycoprotein (Bradley and Ling, 1994) and the
multidrug resistance-related protein, MRP (Cole et al, 1992).
However, alterations other than those involving membrane-associ-
ated drug transport proteins can give rise to a multidrug-resistant
(MDR) phenotype. One such form ofMDR, which has been termed
atypical MDR, is associated with alterations in the expression or
activity oftopo II (reviewed in Beck et al, 1993; Pommier, 1993).
Depending upon their mechanism of action, topo II-targeting
drugs fall into two distinct classes. The members ofone class exert
their cytotoxic effect via the stabilization of a normally transient
reaction intermediate, termed the cleavable complex, which is
formed when the enzyme becomes covalently bound to the 5' ends
of the cut duplex DNA (Liu et al, 1983). Most of the topo II-
targeting drugs currently in clinical use operate via this general
mechanism. Elevated levels oftopo II conferincreased sensitivity to
this class ofdrugs (Davies et al, 1988), while the acquisition ofdrug
resistance is usually associated with a reduction in nuclear topo II
levels (reviewed in Beck et al, 1993; Pommier, 1993). A second
class of topo II inhibitors exert their cytotoxic effects without the
formation ofcleavable complexes. These inhibitors include the thio-
barbiturate derivative, merbarone, and the bis-2,6-dioxopiperazine
derivatives, MST-16, ICRF-193 and ICRF-159 (Tanabe et al, 1991;
Chen and Beck, 1995). These non-cleavable complex-forming
compounds act via the prevention of the reversible opening and
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closing ofthe topo II 'clamp', whichcaptures DNAduringthe catal-
ysis of DNA topology changes (Roca et al, 1994). This class of
'catalytic' inhibitors might be expected to be more toxic to MDR
cell lines expressing reduced levels of topo II, although experi-
mental evidence supporting this notion has not yet been presented.
Here, we have studied whether the same cellular resistance mecha-
nisms operate in response to the two classes of topo II-targeting
agents - those that form cleavable complexes and those that act
independently ofthe formation ofDNA strand breaks.
MATERIALS AND METHODS
Human cell lines
The testicular teratoma cell line SuSa, the breast cancer cell line
MCF-7, the sarcoma cell line MES-SA, the leukaemic cell line
CEM and the two small-cell lung cancer cell lines, NCI-460 and
U1285, togetherwith theircorresponding resistant sublines, SuSa-
VPC2, MCF-7-AdrR, CEM/MX1, MES-SA clone 1-4G11 and
MES-SA clone 05-lF1, NCI-460/pV8 and U-1285-dox800, were
used in this study. All cell lines were maintained in RPMI-1640
medium, supplemented with fetal bovine serum (10%) and the
antibiotics penicillin (100 U ml-') and streptomycin (100 ,ug ml-').
Cells were grown at 37°C in a humidified atmosphere containing
5% carbon dioxide. All cell lines were routinely tested for
Mycoplasma by fluorescence microscopy ofHoecht 33258-stained
cells and were found to be negative.
Clonogenic assays
ICRF-159 was dissolved in dimethyl sulphoxide (DMSO) and
stored in aliquots at -20°C. Adherent cells were seeded at 1000
cells per 9-cm Petri dish, allowed to adhere for 4 h and were then
exposed to different concentrations of ICRF-159 for 24 h. An
equivalent volume ofDMSO to that used in the highest drug dose
was added to the drug-free control plates. Cells were incubated for
14 days to allow colony formation. Colony fixation and staining
were carried out as described previously (Davies et al, 1988).
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Growth inhibition assays
Theeffect ofICRF-159 onthe growth ofthe non-adherent cell lines,
U-1285 and CEM, and their corresponding resistant sublines, U-
1285-dox800 and CEMIMX1, was assessed by growing 2 x 105
cells ml-' in various concentrations ofdrug over a 7-day period and
determining cell numbers at timed intervals using a Neubauer
haemocytometer.
Preparation of mRNA
Total cellular RNA was prepared according to the method of
Chomczynski and Sacchi (1987). RNA concentration was deter-
mined spectophotometrically, and the integrity of the mRNA was
assessed by agarose gel electrophoresis and ethidium bromide
staining.
Ribonuclease protection assays
This procedure was carried out essentially as described by Ausubel
et al (1987). The topo Ila and -P probes used were generated as
described by Jenkins et al (1992). These probes produced protected
fragments of215 bp for topo Ila and two fragments of228 and 296
bp corresponding to the differentially spliced topo Hlp-I and topo
II-2 mRNAs (Davies et al, 1993). The MRP probe (Cole et al,
1992) gave rise to a protected fragment of 270 bp. mRNA expres-
sion levels were determined by densitometric analysis of autoradi-
ographs using a Bio-Image analyser (Milligen/BioSearch). mRNA
levels were equalized in terms ofthe level ofmRNA for an internal
loading control - in this case the housekeeping gene, glycerylde-
hyde-3-phosphate dehydrogenase (GADPH), which produced a
protected fragment of 120 bp.
Western blot analysis
Crude nuclear extracts were prepared as described by Glisson et al
(1986). Samples were equalized in terms of their total nuclear
protein content and then visualized by Coomassie blue staining
of 7.5% sodium dodecyl sulphate (SDS) polyacrylamide gels
(Laemmli, 1970). Samples were transferred from the gel to nitro-
cellulose; the filters were blocked with 2% low-fat milk and then
incubated with either a mouse monoclonal antibody to topoiso-
merase 11a (Cambridge Research Biochemicals) or a rabbit poly-
clonal antibody to topoisomerase II3 (Houlbrook et al, 1995).
RESULTS AND DISCUSSION
Drug resistance characteristics of the cell lines
The drug-resistant cell lines used in this study display the range of
genetic and/or epigenetic changes mostcommonly associated with
resistance to topo II inhibitors. SuSa-VPC2 cells represent a resis-
tant derivative of a testicular teratoma cell line (Hoskins et al,
1994), a cell type that demonstrates exquisite sensitivity to
multiple drugs, both in vitro and in vivo. The MCF-7-AdrR breast
cancer cell line has been shown previously to display marked
overexpression ofP-glycoprotein (Moscow et al, 1989), as well as
increased glutathione-S-transferase (GST) activity (Batist et al,
1986). The CEM/MX1 cell line shows extreme resistance to
mitoxantrone (Danks et al, 1993). With the exception ofthe MES-
SA cells, all of the resistant cell lines were derived by chronic
exposure to a topo II inhibitor. Moreover, these cell lines were
isolated by exposure to several different classes oftopo II inhibitor
(Table 1).
Expression of the topo 11 and MRP genes in drug-
resistant cell lines
The level of topo Ilo and -P mRNA expression in all of the
parental and resistant cell lines was determined using RNAase
protection assays. The data in Figure IA and Table 1 show that the
SuSa-VPC2 subline displayed a reduced level of mRNA for both
topo IIa and topo IlI (fourfold and threefold respectively). The
MCF-7-AdrR subline exhibited a fourfold down-regulation oftopo
Ila mRNA and an approximately tenfold down-regulation of the
two topo IIP mRNA species. A slight downregulation in the
expression of topo Ila mRNA was observed in the NCI-460 pV8
cell line, with no apparent downregulation of the mRNA for the
Table 1 Summary of cell line characteristics
Cell line Selecting agent Fold Topo lla Topo II,B MRP Topo lla Topo II,
(fold resistance sensitivity to mRNA mRNA mRNA protein protein
based on IC50 values) ICRF-1598 levelb levelb levelb leveIc levelc
MCF-7 Doxorubicin 0.70 0.35 . 0.26 2.9 1.1
MCF-7/AdrR (192) 1.2 0.17 (-4 ± 0.8) 0.03 (-12 ± 2.2) 0.47 1.4 0.6
SuSa Etoposide 1.16 0.18 0.21 5.3 3.9
SuSa/VPC2 (8.8) 0.8 0.30 (-4 ± 0.3) 0.07 (-3 ± 0.3) 0.10 2.5 2.8
NCI-460 Etoposide 2.16 0.52 1.54 3.6 7.3
NCI-460/pV8 (9.9) 1.5 1.09 0.30 2.18 2.6 7.0
CEM Mitoxantrone 2.1 1.57 1.30 4.4 8.5
CEM/MX1 (75) - 1.7 0.07 (-22+ 3.8) 1.37 5.3 0.3 (-27.0 3.9)
U-1285 Doxorubicin 4.1 5.7 0.6 6.1 1.4
U-1285/dox800 (3.0) - 3.6 4.0 20.3 (+34 ± 5.9) 4.9 1.4
MES-SA Etoposide 4.7 1.5
05-1Fl1 (1.9) 2.2 (_1O)d (-9.1)4 (1)d 0.9 (-5.5± 1.8) 1.5
1-4G11 (3.4) 5.0 (-33)d (-20)4 (1)d 1.7 (-2.8 ± 0.7) 1.2
aFold sensitivity given for adherent cells only, based on D37 values. bRelative mRNA expression levels as determined by densitometric scanning of
autoradiographs and equalized according to the GAPDH loading control. cRelative protein expression as determined by densitometric scanning of Western
blots. b,cBased on data from at least three independent experiments, fold changes in expression of mRNA and protein levels shown in parentheses (+ increase,
- decrease), only shown if greater than 2.5, ± standard errors. dData from Jaffrezou et al (1994).
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Figure 1 RNAase protection assay to quantify topo Ila and -P mRNA (A)
and MRP mRNA (B) levels in human cancer cell lines and their resistant
counterparts. The samples are arranged in pairs with the parental line on the
left and its resistant derivative on the right, as indicated in each case above
the lanes. The positions of the protected fragments are indicated on the left.
The sizes of the molecular weight standards (in base pairs) are shown on the
right. Densitometric scanning of autoradiograph was performed when each
signal was within the linear range for radiographic film
fP isoform. In contrast, the CEM/MX1 subline showed no alter-
ation in topo Ila gene expression but a 10- to 20-fold down-
regulation of the topo Ilp mRNAs (Figure IA). None of the
;;~~~~~~~~7
I
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Figure 2 Western blot analysis to quantify the level of expression of topo Ila
(A) and f3 (B) proteins in nuclear protein extracts. Samples are shown
arranged in pairs with the parental line on the left in each case and its
resistant derivative on the right, as indicated above the lanes. The position of
the 200 kDa molecular weight standard is shown on the left
aforementioned drug-resistant derivatives showed an altered level
of MRP mRNA expression. In contrast, while the U1285-dox800
resistant cell line showed no significant change in the level oftopo
Ila or -P mRNA expression, it did exhibit a 30-fold overexpres-
sion of the MRP gene (Figure IB). The MES-SA cell sublines,
derived by single-step exposure to low doses of etoposide, have
been reported previously to show down-regulation of both topo
Ila and -P mRNAs, with no alterations in MDRI or MRP gene
expression (Jaffrezou et al, 1994). Thus, the drug-resistant cell
lines studied showed no consistent pattern of altered topo II gene
expression, although down-regulation of the mRNA for one or the
other (or both) topo II isoforms was a general feature of this cell
line panel (Table 1).
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Figure 3 Clonogenic survival curves for parental cell lines and their corresponding resistant counterparts following exposure to increasing concentrations of
lCRF-1 59. (A) SuSa (0), MCF-7 (0~) and NCI-460 (A) parental cell lines and SuSaNVC2 (0), MCF-7 ADrR (0) and 460pV8 (A) resistant sublines. (B) MES-SA
parental cell line (A) and the resistant sublines, 05-1 Fl 1 (7) and 1-4G11 (A). Points represent the mean of three independent experiments
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Figure 4 Growth inhibition assay for parental U-1285 cells and CEM cells (A) and (C) respectively) and the drug-resistant U-1285/dox800 and CEM/MX1
(B and D respectively) cells during exposure to increasing doses of ICRF-159. In each case, the symbols represent the following doses of ICRF-159:
O, no drug; *, 4 ug ml-'; A, 8 g ml-' and D, 16 gg ml-'
The differing patterns ofmRNA expression in the resistant vari-
ants was reflected in levels of topo II protein expression, as deter-
mined by Western blotting of nuclear protein extracts (Figure 2;
Table 1). A similar analysis using whole-cell extracts gave equiva-
lent results (data not shown). However, the degree ofprotein down-
regulation in each resistant variant was generally less marked than
was the degree ofmRNA down-regulation. Indeed, only in the case
of the MES-SA cell-resistant derivatives was the degree of topo II
protein down-regulation greater than 2.5-fold (Table 1).
Measurement of sensitivity to ICRF-159
In order to address whether the panel of drug-resistant cell lines
showed an altered response to a non-cleavable complex-forming
topo II-targeting agent, the parental and resistant variants were
tested for their relative sensitivity to ICRF-159. The data in
Figures 3 and 4 show that none of the resistant cell lines studied
was cross-resistant to ICRF-159. Indeed, the MES-SA 05-FI 1 and
1-4G1 1 cell lines showed collateral sensitivity to ICRF-159. These
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MES-SA-derived cell lines exhibit down-regulation ofboth topo II
isoforms at the mRNA level (Jaffrezou et al, 1994), whereas at the
protein level only the ox isoform appears to be significantly down-
regulated (Figure 2; Table 1).
Relationship between topo 11 expression and sensitivity
to topo Il-targeting drugs
In agreement with many reports, our results show that a decrease
in the level ofthe cellular target (topo II) is associated with relative
resistance to cleavable complex-forming drugs (reviewed in Beck
et al, 1993). This is because the cytotoxicity of these agents is as a
result of their ability to subvert topo II from its normal physiolog-
ical role, in which DNA cleavage occurs only transiently, to one in
which potentially cytotoxic double-stranded DNA breaks persist
in the DNA. Conversely, down-regulation of the target enzyme
might be expected to confer hypersensitivity to non-cleavable
complex-forming topo 1I-targeting drugs, such as ICRF-159,
which act as direct inhibitors of the catalytic activity of the
enzyme. Such a relationship between a 'catalytic inhibitor' and its
target enzyme is well established for drugs that target dihydrofo-
late reductase (reviewed in Fairchild et al, 1990) and thymidylate
synthase (Freemantle et al, 1995). Our study has shown that cell
lines selected for resistance to cleavable complex-forming topo II
inhibitors are not cross-resistant to ICRF-159. This is the case for a
series ofcell lines ofdifferent tissue origin, some ofwhich exhibit
a multidrug-resistant phenotype. This would indicate that overex-
pression of P-glycoprotein, MRP or certain classes of GSTs does
not by itselfconfer resistance to ICRF-159.
Collateral sensitivity to ICRF-159 was seen only in the MES-
SA 05-IFl I and I-4GI I cell lines, despite the finding that some of
the other representatives of this cell line panel showed a modest
level ofdown-regulation oftopo II protein. However, the MES-SA
cell lines did show the greatest degree of topo IIoc protein down-
regulation. Despite this, there was no correlation between the
extent of topo IIoc down-regulation and the degree of ICRF-159
sensitivity in the MES-SA cell lines. Thus, clone 05-IFI1
displayed a lower level oftopo IIo protein than did clone 1-4GI 1,
but both cell lines had similar ICRF-159 sensitivity. Nevertheless
our results are consistent with the notion that the likely target
for ICRF-159 is the topo IIoc protein in human cells and that
down-regulation of the ix isozyme alone can confer sensitivity to
ICRF-159, as the dramatic down-regulation ofthe f isoform in the
CEM/MXI subline did not appear to influence the degree of
ICRF-159 sensitivity. Clearly, further work will be required to
confirm this suggestion. If this proves to be correct, our results
suggest that sensitivity to ICRF-159 may only occur when the
nuclear content of topo IIoc falls below a critical threshold level as
members of the cell line panel other than 05-lFII and 1-4G11
exhibited a small down-regulation oftopo Ila. The level that is set
for this threshold might be dependent upon the requirement in each
cell line for a particular level of topo IIoc activity during chromo-
some segregation at mitosis.
Cells oftesticular germ cell origin are very sensitive, in vivo and
in vitro, to a wide range of drugs, including cis-platinum and
bleomycin. However, the testicular teratoma cell line, SuSa, was
more resistant to ICRF-159 than any ofthe other parental cell lines
studied. The high basal topo II activity in the parental SuSa cell line
(Fry et al, 1991) might be responsible for the intrinsic resistance of
this line to ICRF-159 compared with other epithelial cell lines.
In the clinical situation, where resistance to cleavable complex-
forming topo IL-targeting drugs is encountered all too frequently
(although whether this is conferred by changes in topo II is not
known), it would be interesting to analyse whether patients still
respond to treatment with topo II-targeting drugs, such as ICRF-
159, which act via a distinct mechanism. Bis(2,6-dioxopiperazine)
derivatives have previously been shown to have some anti-tumour
activity in leukaemia and sarcomas. Marrow suppression was the
dose-limiting toxicity in Phase II studies, and use of the drug was
generally discontinued (Tsukagoshi, 1994). Re-evaluation of this
drug (or an analogous agent) may be indicated, in combination
with marrow support provided by colony-stimulating factors.
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